Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Photosensitivity Disorders 1Keratosis, Actinic 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Basal Cell 1

Interventions

Temozolomide 26Radiotherapy 10Bevacizumab 10Carboplatin 6Irinotecan 5pembrolizumab 4Radiation 4Nivolumab 4IL13-PE38 4temsirolimus 3Surgical Procedures, Operative 3Magnetic Resonance Spectroscopy 3Immunotherapy, Adoptive 3Erlotinib Hydrochloride 3Aminolevulinic Acid 3trametinib 2olaparib 2lutetium Lu 177 dotatate 2fludarabine 2dabrafenib 2cemiplimab 2abemaciclib 2Vorinostat 2Transurethral Resection of Bladder 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Imatinib Mesylate 2Flucytosine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioma × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT05736406 2026-05-22

A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Hemerion Therapeutics

Phase 1/2 Active not recruiting
12 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡